Owing to the tumor‐promoting actions of 5‐HT, current therapeutic research is probing strategies to curb tumor growth by targeting 5‐HT levels across various models, to enhance CD8+ T cell infiltration in the TME and reduce PD‐L1 expression [387]. This evidence concerns the gene CD8A and neoplasm.